CA-GRINDR
20.11.2023 10:08:56 CET | Business Wire | Press release
At the outset of European testing week, Grindr Inc. (NYSE: GRND), the world’s largest social network for the LGBTQ+ community, today announced the launch of its new partnerships with Equality Movement and MPOWER to connect Grindr users directly with HIV self-test kits in Georgia and Ireland, respectively. With these partnerships, Georgia and Ireland become the first countries outside of the United States in which Grindr users can order free at-home HIV self-test kits directly from links embedded in the Grindr interface, in less than one minute.
Access to HIV testing continues to be one of the biggest obstacles in the fight against the global HIV epidemic. In-person testing, in particular, poses barriers such as clinic operating hours, transportation, costs, and concerns about privacy or stigma. These barriers become even more pronounced for a variety of Grindr users, such as those living in rural areas, or those who are not “out” to their families. At-home self-testing offers users a convenient and discrete option to protect their health.
Grindr has a long history of promoting both Equality Movement and MPOWER’s home self-testing programs. As it became clear that a significant number of Grindr users needed the level of flexibility and anonymity that home self-testing provides, Grindr decided to partner with both organizations to make this easier than ever. In expanding this collaboration, Grindr emphasizes both organizations’ commitment to implementing community-level interventions and judgment-free resources.
“For the past eight years, it has been my goal to find ways to increase access to HIV testing for Grindr users, and of all the things we’ve experimented with, embedding in-app links to home self-test kits has emerged as the most powerful strategy by a considerable margin,” said Jack Harrison-Quintana, Director of Grindr For Equality. “I could not be more excited to launch partnerships similar to those with Equality Movement and MPOWER around the world.”
“Making free at-home HIV self-testing available directly through the Grindr app helps to ensure members of the LGBTQ+ community have access to vital services they need to protect their health and feel supported in their daily lives,” said Lasha Nonikashvili at Equality Movement. “We are thrilled that the LGBTQ+ community across Georgia will now be able to protect their health with an easy solution they can access from home.”
“This partnership with Grindr has the potential to revolutionize the way our community across Ireland accesses vital at-home HIV self-testing,” said Adam Shanley at MPOWER, whose mission is to devise sex-positive, judgment-free and harm reduction-based resources, services and support for gay, bisexual and MSM in Ireland. “By making these resources more widely available at home, we hope to increase access, reduce stigma, and contribute to the long-term reduction of HIV.”
Today’s announcement builds on Grindr’s commitment to achieving a meaningful impact for the LGBTQ+ community. Earlier this year, we partnered with Building Healthy Online Communities and Emory University to launch Together TakeMeHome (TTMH) with support from the U.S. Centers for Disease Control and Prevention. TTMH is a unique partnership that has distributed over 232,262 test kits within the first six months of the program. Nearly a quarter of those orders were placed by people who had never previously tested for HIV, and a majority were requested through Grindr. Grindr remains committed to launching similar programs for users around the world.
About Grindr Inc.
With more than 13 million monthly active users in virtually every country in the world, Grindr has grown to become a fundamental part of the LGBTQ+ community since its launch in 2009. The company continues to expand its ecosystem to enable gay, bi, trans, and queer people to connect, express themselves, and discover the world around them. Grindr’s impact is further driven by Grindr for Equality’s wide-ranging initiatives that help the LGBTQ+ community around the world. Grindr is headquartered in West Hollywood, California. The Grindr app is available on the App Store and Google Play.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231120646279/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
